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Abstract 
 
Diabetes mellitus (DM) is a major global metabolic disorder 
currently affecting over 450 million people and this number 
is rising rapidly. Heart failure (HF) is the major cause of 
death among diabetic patients. The disorder is due to 
elevated blood glucose level beyond physiological range or 
hyperglycaemia (HG), which in turn leads to a number of 
long-term complications, including diabetic cardiomyopathy 
(DC) over time. Around 80% of all diabetics will eventually 
die from DC. If left untreated, DC has been shown to be a 
critical factor in HF, independent of atherosclerosis, 
hypertension and valvular malfunction. The inability to 
maintain glucose homeostasis in the myocardium 
compromises cardiac structure and function in human 
diabetic subjects and also in animals with experimental 
diabetes. Daily exercise is known to protect the heart from 
sudden cardiac death. Exercise training (ET) is a beneficial 
non-pharmacological intervention for the treatment of 
cardiovascular diseases (CVDs). ET can induce cardio-
protection in normal hearts and also in a partially diseased 
heart through a range of molecular mechanisms. The cardio-
protective effect of ET is associated with the improvement 
of antioxidant capacity, mitochondrial viability and it can 
activate physiological cardiac growth, which are all 
mediated via distinct cellular and molecular mechanisms 
compared to those in pathological hypertrophy. Beneficial 
cardiac protection following regular ET in diabetes has been 
reported in both clinical and experimental animal studies. ET 
is a cost-effective strategy for prevention and treatment DC. 
However, the cellular and molecular mechanisms underlying 
DC and HF in diabetes and how regular exercise can reverse 
the pathology are not fully clear and further research should 
be carried out. 
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Cardiovascular diseases (CVDs) are directly 
linked to DM and are responsible for about 80% of 
mortality in the diabetic population [1]. Diabetic 
cardiomyopathy (DC) is diabetes-mediated, resulting 
in pathological cardiac remodelling in the absence of 
coronary artery disease, hypertension and valvular 
disease. In fact, diabetes is a multi-factorial disease. 
Therefore, the mechanism underlying DC is complex. 
However, an understanding of that mechanism is 
essential for preventing heart failure (HF) caused by 
diabetes or reserving the pathological cardiac 
remodelling [2]. In fact, HF is one of the main causes 
of mortality in the world despite advances in drug and 
treatments [3]. Epidemiological data show that macro-
vascular complications, including coronary artery 
disease (CAD), hypertension, heart failure, peripheral 
vascular disease (PVD) and stroke are more common 
2-4 times among diabetic patients in comparison with 
non-diabetic people [4]. Renal failure and CVDs are 
the two major causes of morbidity and mortality in 
diabetic patients and hearts of diabetic patients are 
frequently in a compromised condition [5]. According 
to the Framingham study, the frequency of CAD is 
twice more common in diabetic patients of both 
genders [6]. DM increases the risk for heart failure by 
progressive weakening of cardiac function. It can also 
affect cardiac structure and function without causing 
changes in blood pressure and CAD [7]. This term was 
introduced in 1972 for the description of 4 patients with 
DM and HF, but without any signs of either 
hypertension or CAD [8]. DC represents the major 
cause of mortality and morbidity among diabetics [9]. 
It has been defined as ventricular dysfunction which 
occurs in diabetic patients independent of a recognized 
cause such as CAD or hypertension. The early stage of 
DC is a hidden subclinical period in which cellular 
structural changes lead initially to diastolic 
dysfunction, later to systolic dysfunction, and 
eventually to HF. The most common contributors to 
DC onset and progression are left ventricular 
hypertrophy, metabolic abnormalities, (mitochondrial 
dysfunction), extracellular matrix changes (fibrosis), 
small vessel disease (endothelial dysfunction), cardiac 
autonomic neuropathy, insulin resistance, oxidative 
stress, and apoptosis, all leading to cardiac remodelling 
[10]. DC is also accompanied by comorbidities such as 
obesity, hypertension and others. These complications 
often precede the development of systolic function, 
CAD and heart failure [11].  
 
Historical Background of Diabetic 
Cardiomyopathy 
 
DC affects the heart by enhancing fatty acid 
metabolism, suppressing glucose oxidation and 
modifying intracellular signalling, all of which lead to 
alteration in multiple steps of the excitation-
contraction coupling (ECC) process, inefficient energy 
production, increased susceptibility to ischemia and 
contractile dysfunction [12]. The exact underlying 
mechanism of DC is still not fully clear, and several 
causes have been proposed including metabolic 
disorder, autonomic dysfunction, and interstitial 
fibrosis [13]. Metabolic disturbances such as altered 
lipid handling and substrate utilization, decreased 
mechanical efficiency, mitochondrial dysfunction, 
disturbances in non-oxidative glucose pathways and 
increased oxidative stress are all hallmarks of DC. 
Thus, the pathogenesis of DC is multifactorial and 
complex, eventually leading to an energetically 
compromised heart with reduced cardiac working 
capacity and heart failure [14]. This review highlights 
the available data about the development of DC, how 
ET may influence cellular, structural and functional 
changes in DC, and in particular, to further explore the 
effect of exercise training (ET) on mitochondrial 
biogenesis in DC and how ET preserves cardiac 
function and prevents myocardial apoptosis and 
fibrosis. Since this review is based on non-
pharmacological intervention to treat DC, then much 
emphasis will be focused on ET as non-
pharmacological intervention in the treatment of heart 
disease. 
 
 
Historical Background of ET as Medicine 
 
The history of ET as a treatment and prevention 
measure may be attributed to the ancient Greek 
Society. Exercise as medicine was first proposed by 
Greek philosophers during the 4th century B.C. 
Furthermore, Hippocrates wrote two books on regimen 
and noted that “eating alone will not keep a man well; 
he must also take exercise” [15]. The effect of ET in 
lowering glycosuria has been evident since 600 B.C, 
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when Shushruta, an Indian Physician, noted the 
reduction in the sweetness of urine from diabetic 
patients after ET [16]. Nowadays, it is well established 
that physical exercise continues to be one of the most 
valuable and cost- effective forms of non-
pharmacological therapy. ET can induce cardio-
protection in normal hearts through a range of 
molecular mechanisms [17]. ET was defined by the 
American College of Sports Medicine as “Any and all 
activity involving generation of force by the activated 
muscle(s) that results in disruption of a homeostatic 
state” [18]. ET is classified by the type, intensity, and 
duration of activity. Endurance exercise reflects 
prolonged and continuous periods of contractile 
activity (high repetition) against low resistance [19]. In 
contrast, resistance exercise (strength training) 
involves short periods of contractile activity (low 
repetition) against a high opposing resistance, while 
sprint exercise occurs during short periods of maximal 
(intense) repetitive contractile activity, where there is a 
short period of exercise against a low resistance, such 
as running a 100-m sprint race. However, sprint 
training can also be performed against high resistance, 
which results in a combination of resistance and 
endurance modalities, for example, running with added 
weights [18]. The beneficial cardiac impact of ET in 
diabetes management has been reported in clinical 
medicine [20, 21] and experimental animal studies [22, 
23]. ET is a low-cost strategy for the prevention and 
treatment of DC. ET has a beneficial impact on 
diabetes-related systemic changes and it may also 
improve the metabolic disturbances of the diabetic 
myocardium. These changes are the result of both 
indirect effects, exercise-mediated systemic changes 
and direct effect originating from the high contractile 
activity of the heart during ET [14]. The cardio-
protective effect of ET is associated with the 
improvement of antioxidant capacity and 
mitochondrial viability and activated physiological 
cardiac growth which are all mediated via distinct 
cellular and molecular mechanisms from those patients 
with pathological hypertrophy [24]. Similarly, in 
animal models, it has been shown that ET can prevent 
ventricular remodelling and attenuated derangement of 
glucose and lipid metabolism, and improve 
mitochondrial function and antioxidant capacity 
leading to ameliorated cardiac performance in early 
stage of DC [24]. 
 
 
 
 
Structural and Functional Changes in DC 
 
DC leads to structural and functional changes in 
the heart. The structural changes are manifested by left 
ventricular hypertrophy, interstitial fibrosis, increased 
cell death or apoptosis and oxidative stress [25, 26]. 
DC also results in functional changes including a 
derangement in cellular calcium homeostasis, diastolic 
dysfunction, systolic dysfunction and impaired 
contractile reserve [27]. In type 2 diabetes (T2DM), 
left ventricular mass is an independent marker of 
cardiovascular risk. It often occurs independent of 
atrial blood pressure. Therefore, diabetes is an 
independent risk factor leading to left ventricular 
hypertrophy and myocardial stiffness [28]. DC is also 
characterized by interstitial fibrosis, mostly composed 
of collagen and perivascular fibrosis [29]. At the 
cellular level, prolongation of cardiac action potential 
duration (CAPD) has been consistently shown in 
diabetic hearts. Significant alterations in the ionic 
currents that constitute cardiac action potential (CAP) 
configuration have been proposed as the main culprit 
of this prolongation [30, 31]. The intracellular free 
Ca2+ concentration [Ca2+]i is very essential for the 
myocardium contraction [32]. DC-induced 
abnormalities during cardiac contractility have been 
correlated with the intracellular Ca2+ changes. Diabetic 
cardiac dysfunction most likely arises due to changes 
in expression and/or activity of cellular mechanisms 
that regulate Ca2+ transport during cardiac cycle [33]. 
Thus, DC results in changes in biomechanical, 
contractile and hypertrophic properties changes of 
cardiac myocytes.  
These changes could be a result of altered 
myocardial glucose and fatty acid metabolism due to 
DM. Chronic hyperglycaemia leads to non-enzymatic 
glycation of vascular and membrane proteins, 
producing advanced glycation end products (AGEs), 
reactive oxygen species (ROS) and reactive carbonyl 
species (RCS) [34]. AGEs may play an important role 
in the pathobiology of heart failure [35]. AGEs are 
either proteins or lipids that become glycated after 
exposure to sugars. They are prevalent in the diabetic 
vasculature contributing to the development of 
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atherosclerosis. Moreover, they have been shown to be 
increased in plasma by hyperglycaemia [35]. 
Accumulation of AGE in collagen was associated with 
reduced collagen turnover, indicating the possibility 
that cross-linking of collagen makes collagen resistant 
to hydrolytic turnover. Such AGE-mediated cross-
linking of collagen is thought to be responsible for 
increased stiffness of arteries and the myocardium. In 
fact, AGEs are increased in the myocardium during 
T1DM and T2DM, and there are positive correlations 
of serum level of AGEs with ventricular isovolumetric 
relaxation time, arterial stiffness, and carotid intimal 
thickness all of which have been shown in diabetics 
[35]. There is a significant increase in the deposition of 
collagen around the vessel and between the myofibres 
of heart biopsies from diabetic patients. In addition, 
deposits of lipofuscin, which are brown pigment 
granules composed of lipid-containing residues, were 
found in left ventricular transmural biopsies. 
Myocardial triglyceride and cholesterol contents in 
these biopsies were measured and significant increases 
in these molecules were found in the heart tissue [2]. 
 
 
DC, Insulin, and Metabolic Alteration 
 
Insulin has a vital role in the regulation of various 
aspects of cardiovascular metabolism and function. In 
fact, the human heart produces and uses between 3.5 
and 5 kg of ATP every day to pump. The energy 
generation depends on the cardiac environment 
including coronary flow, blood substrate supply, 
hormones and nutritional status [36]. Alteration of 
myocardial substrate and energy metabolism are 
considered as significant factors for the development 
of DC [37]. DM is characterized by reduced glucose 
and lactate metabolism and increased fatty acid (FA) 
metabolism [38]. In the diabetic heart, the myocardial 
glucose transport is impaired because of decreased 
myocardial concentration of GLUT1 and GLUT4 
protein and mRNA level [39]. A second mechanism of 
reduced glucose oxidation is via the inhibitory effect of 
fatty acid oxidation on pyruvate dehydrogenase 
complex due to high circulating FFA [40]. Insulin 
induces glucose uptake in cardiomyocytes by binding 
to insulin receptor (IR). IR undergoes auto-
transphosphorylation which initiates a signalling 
cascade initiated by tyrosine phosphorylation of insulin 
receptor substrates (IRS), followed by phosphorylation 
of phosphatidyl-inositol-3 kinase (PI3K), 
phosphoinositide-dependent kinase 1 (PDK1), Akt, 
and protein kinase C (PKC). These events lead the 
glucose transporter type 1 (GLUT1) and type 4 
(GLUT4) translocation to the membrane to facilitate 
glucose uptake into the cell. In the heart, contractile-
mediated translocation of GLUT4 represents the major 
mechanism that regulates glucose entry in the beating 
heart, with GLUT1 playing a lesser role [41].  
Insulin resistance and hyperinsulinemia are 
recognized as risk factors for DC [42]. In 
hyperinsulinemia and insulin resistance, a disturbance 
of insulin-mediated glucose metabolism occurs which 
can significantly worsen metabolic efficiency of both 
skeletal and cardiac muscle. Insulin affects the diabetic 
heart by both systemic metabolism abnormalities and 
direct effects on insulin signalling pathways that are 
intrinsic to the cardiac tissue [43]. In the evolution of 
insulin resistance, the initial change that develops in 
the hearts of animal models is the impairment in the 
ability of insulin to increase glucose transport [44]. A 
recent study revealed that insulin resistance is 
associated with cardiac contractile dysfunction. The 
authors of the study generate a new insulin resistant 
animal rat model on high cholesterol fructose (HCF) 
diet. HCF diet induced insulin resistance on both 
metabolic response tissue and the heart as well. These 
findings illustrate that insulin resistance is associated 
with metabolic alteration and consequently leading to 
the development of DC [43]. Circulating FAs and 
triglycerides (TGs) are increased by enhanced lipolysis 
in adipose tissue and lipoprotein synthesis in liver, 
resulting in hyperglycaemia and insulin resistance. 
When the FAs exceed the oxidative capacity of the 
heart, the FAs are converted to lipid-like TG or 
ceramide which can lead to lipo-toxicity and cell 
apoptosis [45]. Thus, DM leads to increased rates of 
FA oxidation and decreased rates of glucose oxidation.  
 
 
DC and Fibrosis 
 
Interstitial and perivascular fibrosis is a 
histological symptom of DC [8]. The extent of fibrosis 
correlates with heart weight. The pathogenesis of 
fibrosis in the diabetic heart is proposed to be due to 
diabetic micro-angiopathy. When the diabetic heart is 
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affected by hypertension or CAD, there may be 
additive micro-angiopathy and large vessel-induced 
ischaemia leading to diffuse myocardial scarring. The 
generalized fibrosis can result in increased wall 
stiffness and diastolic dysfunction [46]. Activation of 
the renin-angiotensin system (RAS) is known to have 
a role in the development of DC [40]. In the diabetic 
heart, Angiotensin II (Ang-II) receptor density and 
mRNA expression are elevated [47]. The activation of 
RAS in DM is associated with increased oxidative 
damage, fibrosis and cell apoptosis [48]. Inhibition of 
the RAS was shown to reduce reactive oxygen species 
(ROS) production in streptozotocin-induced type 1 
diabetic rats, similar to the effect observed with 
antioxidant treatment [49]. Ang-II, given exogenously 
to rodents, has been shown to cause cellular changes 
within myocardium leading to hypertrophy and fibrosis 
[50].  
 
 
Mitochondrial Dysfunction 
 
Mitochondria play a significant role in energy 
production in cells. They are also involved in other 
phenomena such as ion homeostasis, free radical 
production, and ultimately cell death [51]. 
Mitochondria are the center of fatty acid and glucose 
metabolism. Diabetes can lead to impaired metabolism 
associated with mitochondrial dysfunction. Recent 
studies have shown ultrastructural and functional 
changes of diabetic cardiac mitochondria. DM affects 
the protein composition of diabetic mitochondria [52]. 
In a model of chronic type 1 diabetic mice, damage to 
mitochondria was indicated by impaired function and 
ultrastructure abnormalities. Damage was 
accompanied by indicators of mitochondrial 
biogenesis, including increases in 11 specific 
mitochondrial proteins, elevation of mRNA for the 
mitochondrial regulatory protein and increased total 
mitochondrial DNA area and number. These findings 
showed that mitochondria are a major focus of 
diabetes-induced damage to the heart [53]. Along with 
those findings, DM also leads to a decrease in 
mitochondrial efficiency for ATP production.  
A recent study demonstrated the relationship between 
impaired insulin signaling and altered mitochondrial 
energetics by using mice with a cardiac-specific 
deletion of the insulin receptor. In the study, the 
authors found that impaired myocardial insulin 
signaling promotes oxidative stress and mitochondrial 
uncoupling, which, were accompanied with reduced 
fatty acid oxidative capacity and impaired 
mitochondrial energetics [54]. Diabetic mitochondria 
also produce more ROS than normal mitochondria 
[55]. According to the molecular theory of DC, 
hyperglycemia (HG) is the main pathogenic factor 
[56]. HG stimulates the overproduction or 
pathophysiological levels of ROS and reactive 
carbonyl species (RCS). ROS and RCS are significant 
contributors to structural and functional abnormalities 
of the myocardium [56]. Mitochondria are the major 
source of ROS and RAC productions and depletion of 
antioxidants as depicted in the flow diagram of Figure 
1. 
 
 
Figure 1. Flow diagram showing how DM can lead to 
hyperglycaemia and oxidative stress which in turn induced 
the production of ROS and RCS and a decrease in anti-
oxidant capacity of the myocardium during diabetic 
cardiomyopathy. 
Cellular sources of ROS generation within the 
heart include cardiac myocytes, endothelial cells and 
neutrophils. ROS induces cellular damage through 
many mechanisms including oxidation, interference 
with nitric oxide and modulation of detrimental 
intracellular signaling pathways. Thus, increased ROS 
leads to cardiac dysfunction by direct damage to 
proteins and DNA resulting in apoptosis [57]. RCS are 
diverse in chemical structures generated in different 
cell types including vascular smooth muscle cells of 
the body. They are derived from multiple sources, 
including auto-oxidation of glucose and lipids, triose 
pathway fluxes and from enzymes such as 
semicarbazide–sensitive amine oxidases and 
methylglyoxal synthase. In contrast, RCS also have 
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unique characteristic compared to ROS in that their 
half-lives are longer (minutes vs millisecond), and they 
are uncharged molecules, allowing them to migrate far 
distance from their site of production [58]. 
 
 
Impaired Ca2+ Homeostasis 
 
Ca2+ is a major trigger, initiator, modulator, second 
messenger and regulator (signaling mechanism) of 
cardiac contractility. Most of the Ca2+ that activates 
contraction is released from sarcoplasmic reticulum 
(SR) through ryanodine receptors (RyRs). RyRs are 
themselves activated by the inducing Ca2+ through 
activation of voltage-dependent L- type Ca2+ channels 
and this mechanism is known as Ca2+-induced Ca2+ 
release (CICR) [59]. The cytosolic Ca2+ ions in turn 
interact with contractile proteins. By binding to 
troponin C, the Ca2+ triggers the sliding of thin and 
thick filaments resulting in cardiac muscle contraction. 
Ca2+ then returns to diastolic levels mainly by 
activation of the SR Ca2+ pump (SERCA2a), the 
sarcolemma Na+-Ca2+ exchanger (NCX), and the 
sarcolemma Ca2+ ATPase [7]. DM leads to 
mitochondrial dysfunction which contributes to the 
development of DC by altering ATP generation and 
Ca2+ movement as illustrated in Figure 2 [60]. 
Furthermore, it has been suggested that HG is 
associated with the alteration of the expression and 
function of RyRs and SERCA and this alteration may 
lead to impair myocardial systolic and diastolic 
function [27]. Thus, Ca2+ homeostasis is altered in DC 
by affecting the ability of SR to take up Ca2+ and the 
Na+-Ca2+ exchanger, and the sarcolemma Ca2+ ATPase 
to pump Ca2+ out of the cell [61, 62], all leading to 
elevated diastolic Ca2+. In streptozotocin (STZ)-
induced type 1 diabetic rats, a depression in contraction 
and relaxation in myocytes was found in parallel with 
depression in the rise and decline of intracellular free 
Ca2+ concentration. The SR Ca2+ store and rates of Ca2+ 
release and reuptake into SR were depressed and the 
rate of Ca2+ efflux via sarcolemma Na+-Ca2+ exchanger 
was also depressed. The depression in SR function was 
associated with decreased SR Ca2+-ATPase and 
ryanodine receptor proteins and increased total and 
non-phosphorylated phospholamban proteins [63]. In 
DC, prolongation of cardiac action potential duration 
(CAPD) and slower decay of Ca2+ transient are 
consistently observed in DC. As for prolongation of 
CAPD, reduction in transient outward K+ (Ito) current 
has been shown in animal models of diabetes [64]. 
There is also a reduced expression of L-type Ca2+ 
channel activity which is also an additional 
abnormality in the heart [65]. The prolongation of APD 
is potentially a compensatory mechanism for 
preserving Ca2+ influx in cardiomyocytes with down-
regulated L-type Ca2+ channel [66]. 
 
 
ET Effects on Glucose Transport 
 
In 1982, the increase in sensitivity of glucose 
transport process in skeletal muscle after ET was 
discovered. It was reported that ET could increase 
insulin sensitivity and moreover, it was shown that a 
session of swimming could lead to an increase in 
muscle glucose uptake in the absence of added insulin 
that could be measured in perfused rat muscle after 
cessation of ET [67]. These results were confirmed by 
Garetto et al. [68] in a study in which they showed that 
enhanced glucose uptake after ET occurred in two 
phases. The first phase is independent of added insulin 
and, as this increase in glucose transport was reversed, 
it was replaced by an increase in insulin sensitivity [68-
70]. Subsequent studies have established that 
contractions can stimulate glucose transport in the 
complete absence of insulin [71-73] and that the 
maximal effects of contractions and insulin are additive 
in nature. Moreover, both contractions and insulin can 
stimulate glucose transport by separate signaling 
pathways. The initial steps in the signaling pathways 
by which contractions stimulate glucose transport have 
been identified in the heart [69]. One of these is the 
release of Ca2+ from the SR resulting in activation of 
Ca2+/calmodulin-dependent protein kinase (CaMK) II, 
which is the isoform of CaMK found in skeletal muscle 
[74]. This process can be studied using sub-
concentrations of agents such as caffeine, that release 
Ca2+ from the SR. Studies using this approach have 
shown that either the inhibition of Ca2+ release from 
the SR, or inhibition of CaMKII can prevent the 
increase in glucose transport induced by Ca2+ [69, 74].  
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Figure 2. Flow diagram showing changes occurring in the heart during diabetic cardiomyopathy. DC can lead to structural, 
functional and biochemical changes at cellular and subcellular levels. 
 
Athlete’s Heart 
 
In clinically healthy individuals, regular high-
intensity physical activity for 5 to 6 hours per week 
may lead to cardiac adaptation known as an athlete’s 
heart resulting in compensatory myocardial 
hypertrophy [75]. Acute responses to endurance ET 
include significant increases in maximum oxygen 
consumption, cardiac output, stroke volume and 
systolic blood pressure, all of which are associated with 
decreased peripheral vascular resistance. However, 
long-term cardiovascular adaptation to dynamic 
training results in increased maximal oxygen uptake 
due to increased cardiac output and arteriovenous 
oxygen difference. Strength exercise results in little or 
no increase in oxygen uptake. Thus, endurance 
exercise predominantly produces volume load on the 
left ventricle (LV), and strength exercise causes largely 
a pressure load [76]. LV physiological hypertrophy is 
caused by a proportional increase in myocardial cell 
length and width without evidence of myocardial 
hyperplasia in the majority of cases and this is 
mediated via increased cardiac insulin-like growth 
factor-1 (IGF-1) expression and activation of 
phophoinositide-3 kinase (PI3K) [77]. 
Physiological and pathological cardiac 
hypertrophies are caused by different stimuli and 
functionally distinguishable as illustrated in Table 1. A 
pathological stimulus causing pressure overload like 
aortic stenosis or hypertension produces an increase in 
systolic wall stress which results in in concentric 
hypertrophy (heart with thick wall relatively small 
cavities) [75]. However, pathological stimulus can 
cause volume overload resulting in aortic regurgitation 
or arteriovenous fistula. This produces an increase in 
diastolic wall stress resulting in eccentric hypertrophy 
 
Diabetes Mellitus (Hyperglycemia) 
 
Diabetic cardiomyopathy 
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(heart with large dilated cavities and relatively thin 
wall). For the physiological hypertrophy, isotonic 
exercises such as walking, running and cycling involve 
movements of large muscles resulting in an increase in 
venous return and the increased volume will lead to 
eccentric hypertrophy. Generally, physiological 
concentric hypertrophy is caused by isometric or static 
exercise such as weight lifting which involves 
muscular tension against resistance with little 
movement. Reflex and mechanical changes rather than 
volume can cause a pressure load on the heart [78]. 
Function of the pathological hypertrophied heart may 
eventually decompensate leading to left ventricle 
dilation and heart failure, while in physiological 
hypertrophy, it does not decompensate compared to 
dilated cardiomyopathy of heart failure [75]. Thus, ET 
can result in a beneficial physiological, rather than an 
abnormal pathological growth. 
ET-induced adaptation of the coronary circulation 
can be divided into two main processes. The first 
process is angiogenesis leading to an expansion of the 
capillary network by the formation of new blood 
vessels. This occurs at the level of capillaries and 
resistance arterioles, but not in large arteries. The 
second process involves arheriogenesis which can 
result in the enlargement of existing blood vessels [79].  
The molecular mechanisms underlying 
angiogenesis induced by exercise training are not fully 
understood. It has been suggested that growth factors 
such as vascular endothelial growth factor (VEGF), 
fibroblast growth factor (FGF) and angiopoietins 
(AQP), as well as their corresponding receptors, are 
involved in the process. In addition, proteases 
necessary for the degradation of the capillary basement 
membrane such as matrix metalloproteinases (MMPs), 
urokinase, tissue plasminogen activator and 
plasminogen, are also likely to contribute to the 
mechanism of sprouting angiogenesis [80]. 
 
 
Table 1: Table showing the changes which occur in the heart during ET and DC 
 
Heart 
remodeling 
Exercise Training Diabetic Cardiomyopathy 
Hypertrophy Physiological hypertrophy does not 
decompensate to dilated cardiomyopathy of 
heart failure [75]. 
Pathological hypertrophy eventually 
decompensates leading to left ventricle dilation and 
heart failure [75]. 
Metabolism Fatty acids and lactate are the major 
substrates for the heart during exercise [81]. 
Also increased rates of glucose oxidation 
and glycolysis [82] 
Associated with reduced glucose and lactate 
metabolism, as well as increased fatty acid 
metabolism [38]. 
Oxidative 
stress 
Decreasing reactive oxygen species (ROS) 
by dampening the activators of ROS 
producing enzymes [83]. 
Overproduction of reactive oxygen species (ROS) 
and reactive carbonyl species (RCS) [56]. 
Cellular 
Ca2+  
homeostasis 
Effectively restoring myocardial expression 
and activity of sarcoplasmic reticulum  
Ca2+  ATPase- pump (SERCA) [84]. 
Altering Ca2+ movement [60] by affecting the 
ability of SR to take up Ca2+, and the Na+-Ca2+ 
exchanger and the sarcolemma Ca2+ ATPase to 
extrude Ca2+ from the cell [61] 
 
 
 
Non-Pharmacological Intervention  
for DC Treatment 
 
The first recognition of ET as a non-
pharmacological option to prevent and treat CVDs was 
in 1890s by Robert Babcock [85]. He stated that 
“Improved arterial circulation is so manifest a result of 
these exercises that lessen the frequency, nay, even the 
severity of attacks of angina pectoris in individuals 
with arteriosclerosis who had been unable to indulge in 
even very moderate physical exercise taken in the 
ordinary ways of walking.” Currently, regular ET is a 
valuable therapeutic method/tool, and evidence from 
the scientific and medical communities strongly 
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supports the need to integrate the practice of regular ET 
in the therapeutic management of the disease and to 
limit diabetic-related long-term complications [86]. In 
fact, ET improves metabolic control and 
cardiovascular fitness. Many clinical studies have 
found that ET decreases cardiovascular risk factors 
[87, 88]. Similarly, several scientific reports have 
shown the advantages of ET on cardiac function and 
structure of diabetic patients, as well as in experimental 
models of DM, including reduced fibrosis, hypertrophy 
and apoptosis of the myocardium [89, 90]. Regular 
exercise is very important for maintenance of LV mass 
and function. As studied in bed-rest trials, prolonged 
physical inactivity leads to significant reductions in LV 
mass and impaired cardiac compliance, resulting in 
reduced upright stroke volume and orthostatic 
intolerance [91]. Since DC is associated cardiac 
remodeling (CR) which is characterized by myocardial 
hypertrophy, fibrosis and apoptosis, physiological 
hypertrophy in response to ET may differ in its 
structure and molecular profile to pathological 
hypertrophy [78].  
The beneficial effect of exercise on coronary artery 
function has been demonstrated in diabetic rodent 
models [92, 93]. Since cardiac tissue has an extremely 
high metabolic demand, consequently, cardiac 
function is highly dependent on adequate coronary 
blood flow. Thus, coronary artery dysfunction directly 
impacts on optimal myocardial function. An eight-
week moderate-intensity exercise regime in 
individuals with T2DM significantly improved 
endothelial cell function in the brachial artery as 
indicated by the improved flow-mediated dilation [94]. 
In another study, a 14-month moderate-intensity 
resistant training in adults with T2DM improved 
endothelial cell function-dependent and -independent 
vasodilation in response to acetylcholine and sodium 
nitroprusside, respectively [95]. Repeated exercise 
sessions may stimulate other adaptive changes which 
can contribute to both improved insulin sensitivity and 
metabolic health. Increased oxidative capacity and 
capillary density were observed in skeletal muscle in 
response to aerobic exercise [96]. In addition, 
increased adipose tissue insulin sensitivity has been 
observed 72-hours after completion of a 6-week 
exercise intervention [97]. 
 
 
ET Impact on Cardiac Metabolism in Health 
and During DC 
 
Metabolic flexibility is the ability of the heart to 
ensure sufficient ATP production rate under diverse 
physiological and dietary conditions. The lack of this 
flexibility has been regarded as fundamental in the 
development of heart failure, including DC [98]. ET 
has an impact on cardiac metabolism. An acute 
exercise session can result in alteration of metabolic 
state by high level of plasma lactate from glycolysis in 
exercising muscle and non-esterified FAs. FAs and 
lactate are the major substrates for the heart during 
exercise [81]. In STZ diabetic rats, ET results in 
increased rates of glucose oxidation and glycolysis 
[82], while FA oxidation was unaltered [99]. 
 
 
ET and Oxidative Stress 
 
It is now well established that increased ROS and 
RCS productions can lead to cardiac dysfunction by 
direct damage to regulatory proteins and DNA and 
induced apoptosis. Moreover, ROS producing 
enzymes are influenced by long-term endurance 
exercise training, through very different mechanisms. 
ET leads to improvement of insulin signaling, reduced 
inflammatory status, alteration of plasma lipids, and 
reduced RAS. Most likely, ET participates in 
decreasing ROS in the diabetic cardiomyocyte by 
dampening the activators of ROS-producing enzymes. 
It was reported that the exercise-induced elevation of 
mitochondrial ROS production was attenuated in 
cardiac mitochondria from endurance trained rats [83]. 
Theoretically, tissues with fewer cell divisions are 
more susceptible to cumulative damage by ROS 
compered to tissues with high replication rates [100]. 
One of the most frequently used bio-markers that 
provides an indication of the overall lipid peroxidation 
level is the plasma concentration of malondialdehyde 
(P-MDA), one of several byproducts of lipid 
peroxidation processes [78]. In animal models of 
ageing, increased malondialdehyde levels were 
observed in sedentary old rats. Although the expression 
of anti-oxidative enzymes such as superoxide 
dismutase (SOD) was unchanged, its enzymatic 
activity was reduced resulting in a net decline of anti-
oxidative protection. Regular ET seems to delay the 
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accumulation of ROS-mediated cell damage by 
improving the anti-oxidative protection in the 
myocardium [100]. 
 
 
ET and Ca2+ Homeostasis 
 
Calcium homeostasis has a major role in the 
process of contraction and relaxation (ECC) of the 
heart. ET has been shown to improve cardiac myocytes 
contractility in diabetic models and this improvement 
was associated with improvement of Ca2+ homeostasis. 
ET also prevents the development of DC and the 
dysregulation of SR protein content in an inducible 
animal model of T2DM [22]. Regular ET can 
effectively lead to restoring myocardial expression and 
activity of SERCA and L-type Ca2+channel activity 
[84]. The release of Ca2+ from the internal SR via type 
2 ryanodine receptor (RyR2) is an integral step in the 
cascade of events leading to cardiac muscle contraction 
[101, 102]. Recent studies showed that ventricular 
myocytes isolated from streptozotocin (STZ)-induced 
type 1 diabetic rat hearts exhibited increased frequency 
of spontaneous Ca2+ sparks. In longer term or more 
severe experimental diabetes, reduction in steady-state 
levels of RyR2 and other Ca2+ cycling proteins also 
contribute to the process [63, 103]. RyR2 becomes 
leaky during diabetes and this defect may be 
responsible for the reduced SR Ca2+ load. Diastolic 
Ca2+ release could also serve as a substrate for delayed 
after-depolarizations, contributing to the increased 
incidence of arrhythmias and sudden cardiac death in 
T1DM [102]. Alterations in the sensitivity of RyR2 to 
Ca2+ activation could result of oxidation in the RyR2 
by either ROS or RCS [104]. Time to peak myocyte 
Ca2+ transient was prolonged by light and moderate 
exercise initiated 2 months after the onset of diabetes 
[105]. To date, the effect of ET during diabetes on 
myocyte intracellular Ca2+ cycling and the function of 
SR proteins remain poorly understood. 
 
 
Psychological Intervention to Enhance  
ET Adherence 
 
ET should be considered an essential therapeutic 
tool which has a beneficial effect on DC. In fact, the 
beneficial effects of ET have been observed to wane 
within 3 to 10 days or even longer following exercise. 
Therefore, effective ET therapy programs are 
associated with high ET adherence, as this would 
ensure long-term glycemic control [106].  
Several factors create obstacles to ET, for example 
low motivational status, self-efficacy, negative 
learning history with exercising, lack of coping skills 
and aversive environmental characteristics such as 
reduced access to physical activity facilities, high costs 
of training programs, low social and cultural support 
and time barriers. Improving adherence to ET is a 
critical challenge. In order to promote adherence to ET, 
combined supplementary psychological intervention is 
extremely effective in encouraging the attendance to 
the exercise program [107]. In addition, national health 
services throughout the world should prescribe regular 
daily exercise to patients suffering from DC and other 
related diseases.  
 
 
Conclusion 
 
DM is a major metabolic disorder which can lead 
to damage and subsequent failure to a number of 
organs in the body including the heart where 
hemodynamic disturbances frequently occur. Figure 2 
summaries the processes and mechanism(s) whereby 
DM can lead to DCM subsequently and heart failure. 
Initially, these are induced at sub-cellular, cellular, 
molecular and interstitial levels in the heart, including 
changes in size, shape and function of the myocardium. 
Diabetes, if left untreated, can result in hyperglycemia-
induced generation of ROS and RCS, endothelial and 
mitochondrial dysfunctions, structural changes to 
cardiomyocytes, infiltration of fibrosis, apoptosis or 
death of some cardiomyocytes, followed by 
hypertrophy, disturbances in cellular calcium 
homeostasis, myofilaments insensitivity to calcium 
and subsequently delayed contraction and prolonged 
relaxation all leading to remodeling of the 
myocardium. Most of these changes in the heart can 
either be delayed or prevented by regular ET, which is 
a valuable non-pharmacological therapeutic tool. It is 
now highly recommended by scientific and medical 
communities, which strongly support the need to 
integrate the practice of regular ET in the therapeutic 
management of the disease and to limit diabetic-related 
complications. Of particular importance, ET can also 
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improve metabolic control and cardiovascular fitness. 
Many clinical studies have found that ET decreases 
cardiovascular risk factors. However, the cellular and 
molecular mechanisms underlying DC and heart 
failure in diabetes are not fully clear and further studies 
should be done to unravel the process.  
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